"Chemotherapy is a setting of hormone refractory prostate cancer has shown palliative benefit especially with substantial PSA decline strongly suggesting that disease modifying potential exists. Recently, chemotherapy is beginning to show a survival advantage. The stage is set for chemotherapy given earlier in a disease course. As a working hypothesis, we suspect that the transformation from an androgen-dependent to an androgen-independent phenotype is mediated by the expansion of an androgen-independent clone already present at the time of androgen deprivation. If this model is correct, then it would be desirable to bring treatment to bear on the androgen-independent component when the corresponding tumor burden is minimal. Thus, we view the androgen-independent component as analogous to “microscopic residual” or “micro-metastatic” disease for which adjuvant chemotherapy has shown to be effective in other contexts."
This boils down to early intervention of chemotherapy using two different infusion agents each paired up with two different orals plus 30 mg of Prednisone (has Cancer killing properties) over a six month period. The Trial cohort:
"Forty-six patients were enrolled, and forty-five patients were evaluable. Median progression-free survival (PFS) was 23.4 months. Median overall survival (OS) was 53.7 months. Out of 45 patients with measurable disease, 22 patients had an objective response: 9 patients achieved a complete response; 2 patients achieved a partial response; 10 patients achieved stable disease. Frequent grade 3 adverse events included elevated ALT (17 %), hypokalemia (13 %), and hypophosphatemia (13 %). Grade 4 adverse events were rare and included low bicarbonate (2 %), hypokalemia (2 %), leukocytopenia (2 %), and neutropenia (2 %)."
I am one of the nine. I enrolled within 45 days of confirmed metastatic disease. My thought process was simply, hit the cancer hard when first diagnosed while my body was strong and the cancer was not yet totally involved. Yes, I was offered palliative ADT to delay further onset, but I was not interested. I asked both of my Radiation Oncologists if they were in my shoes with metastatic disease, what would they do. Second question was do you know one. One did not the other sat on a taskforce with one and the rest is history.
I know that Dr. Amato has aggressively treated over 500+ with similar results.
Actually the 350 was because I inadvertently used 2 mg instead of 4 mg. Normal ranges from 550 to 650 depending on Day administered verses day of blood draw. Androgel is short term with a very short half life. Thanks.
He was out from May to July on a Medical leave of absence. If I remember right, FDA was back 12-13 years ago. An employee failed to maintain some records, etc. Never bothered me. I am pleased and he is my Hero!
Thanks. Your response to his treatment seems extraordinary; something all of us high risk cases dream about.
Why do you think you had such success? Is his regimen supported by peer review? What is unique about his treatment compared to the “standard of care”?
Thank you.
Bob
Interesting to see that you found a doctor who isn't afraid to prescribe T supplementation after treatment for PC. That is something I want to look into.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Metastatic Prostate Cancer
Appointment with Provenge doctor
NCT04662580 - All about ARX517 as Monotherapy
primary tumor
Help Understanding My Dad's Biopsy Scores
